A Phase I/II Study of Immunotherapy with Milatuzumab (hLL1) in Patients with Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of milatuzumab that can be given to patients with NHL or CLL. The goal of the Phase II part of this clinical research study is to learn if milatuzumab can help to control NHL or CLL. The safety of the study drug will also be studied.
Treatment Location: N/A
1) The primary objectives are to evaluate the safety and tolerability of milatuzumab, and to determine the maximum tolerated dose (MTD) regimen (in terms of a dose and its associated dosing schedule). 2) The secondary objectives are to obtain information on efficacy, pharmacodynamics, pharmacokinetics, and immunogenicity, and to determine the optimal dose for subsequent studies.
IRB Review and Approval Date: 05/21/2008
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
Phase I/Phase II
For general questions about clinical trials: